Leniolisib-d5

Leniolisib-d5 is a deuterated labeled Leniolisib[1]. Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

Product Specifications

Product Name Alternative

CDZ173-d5

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Isotope-Labeled Compounds; PI3K

Type

Isotope-Labeled Compounds

Related Pathways

Others; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

98.78

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C(C(F)(F)F)C=C(N2CC(C(N[C@H]3CCN(C(C([2H])([2H])C([2H])([2H])[2H])=O)C3)=NC=N4)=C4CC2)C=N1

Molecular Formula

C21H20D5F3N6O2

Molecular Weight

455.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980. |[2]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.